Product Details:
Brand | alimta |
Packaging Type | vial |
Composition | pemetrexed |
Drug Name | pemetrexed |
Packaging Size | vial |
Dose | 500mg |
Dose/Strength | 500mg |
Dosage Form | vial |
We are engaged in offering Alimta, which is used in combination with cisplatin for treatment of metastatic nonsquamous non-small cell lung cancer. Our range is prescribed for the patients, whose disease has not progressed after 4 cycles of platinum-based 1st-line chemotherapy or as a single agent after prior chemotherapy. We offer these products in customized packaging and at cost effective prices to our valued clients.
Other Information
Pay Mode Terms: L/C (Letter of Credit), D/A (Documents against Acceptance), D/P (Documents against Payment), T/T (Bank Transfer), Western Union, Other
Product Details:
Dose | 500mg |
Product Type | Finished Product |
Dosage Form | Injection |
Brand | astrazeneca |
API Form | Powder |
Medicine Type | Allopathic |
Packaging Type | Bottles |
Product Details:
Manufactured By | lilly |
Usage/Application | cancer |
Product Type | injection |
Packaging Type | vial |
Dose/Strength | 500mg |
Gender | Unisex |
Dosage Form | injection |
Form of Medicine | vial |
Brand | alimta |
Usage | Personal |
Alimta is approved for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy.
Available As: 100 Mg Injection & 500 Mg Injection
Additional Information:
Product Details:
Manufactured By | lilly |
Dosage Form | injection |
Dose/Strength | 500mg |
Usage | Personal |
Packaging Type | vial |
Gender | Unisex |
Form of Medicine | vial |
Brand | alimta |
Usage/Application | cancer |
ALIMTA® (pemetrexed for injection) is approved by the FDA in combination with (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have different type of NSCLC called squamous cell.
To Maintain the Effect of Initial Chemotherapy Before Worsening of Advanced or Metastatic Nonsquamous Non-Small Cell Lung CancerALIMTA is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.
If Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer ReturnsALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.
Treatment for Malignant Pleural MesotheliomaALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with , another anticancer medicine (chemotherapy), when surgery is not an option.
Additional Information:
Product Details:
Manufactured By | lilly |
Product Type | injection |
Drug Name | pemetrexed |
Application/Usage | cancer |
Packaging Type | vial |
Dose/Strength | 500mg |
Gender | Unisex |
Dosage Form | vial |
Form of Medicine | injection |
Storage Condition | room temprature |
Quantity Per Pack | 500mg |
Brand | alimta |
Usage | Commercial |
Alimta 500mg
Alimta Supplier
Alimta Lilly
Additional Information:
Product Details:
Brand | Pemgem |
Packaging Type | vial |
Usage/Application | inj |
Composition | Pemetrexed |
Drug Name | Pemetrexed |
Dose/Strength | 500mg |
Dosage Form | vial |
Form of Medicine | Injection |
Generic Content-Pemetrexed, Manufactured By: Dr.Reddy’s Lab,India
Pemgem is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. Pemgem is not indicated for patients who have a different type of NSCLC called squamous cell.
4.1/5
Rated by 94 Users